newsfilter
← Latest News
GlobeNewswire·

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of